{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"1410"},{"groupId":"OG002","value":"624"}]}],"title":"Breast"},{"categories":[{"measurements":[{"groupId":"OG000","value":"305"},{"groupId":"OG001","value":"691"},{"groupId":"OG002","value":"225"}]}],"title":"Lung"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"386"},{"groupId":"OG002","value":"671"}]}],"title":"Lymphoma (DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"332"},{"groupId":"OG002","value":"119"}]}],"title":"Ovarian"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"278"},{"groupId":"OG002","value":"95"}]}],"title":"Prostate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"37"}]}],"title":"Multiple myeloma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"44"}]}],"title":"Bladder"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"851"},{"groupId":"OG002","value":"473"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"795"},{"groupId":"OG001","value":"3320"},{"groupId":"OG002","value":"1815"}],"units":"cycles"}],"description":"Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes.\n\n\\^ 168 cycles in which ZARZIO® was initiated on day 4 or later involved regimens deemed by the Study Steering Committee to be suitable for GCSF initiation any day after chemotherapy (day 1 or later), e.g., etoposide; hence, these patients were re-classified as being within guidelines\n\nDLBCL- Diffuse Large B-Cell Lymphoma. Guidelines refers to EORTC 2010 guidelines","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (EP2006 initiation during chemotherapy, day 0).","id":"OG000","title":"EP2006: EP2006 Initiation During Chemotherapy (Day 0)"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (EP 2006 initiation per guidelines (days 1-3).","id":"OG001","title":"EP2006: EP 2006 Initiation Per Guidelines (Days 1-3)"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (EP2006 initiation later (day 4 or more).","id":"OG002","title":"EP2006: EP2006 Initiation Later (Day 4 or More)^"}],"paramType":"NUMBER","populationDescription":"Number of cycles with initiation on different days during chemotherapy for evaluable sample. A patient may have initiated EP2006 during chemotherapy on different days for different cycles. The categories therefore are not mutually exclusive on a patient level and the sum of patients may therefore exceed the sample size.","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Day of Initiation Relative to Guidelines by Cancer Type","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"cycles"}